File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis - a preliminary study

TitleThe pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis - a preliminary study
Authors
Issue Date1991
PublisherPacini Editore SpA. The Journal's web site is located at http://www.clinexprheumatol.org
Citation
Clinical And Experimental Rheumatology, 1991, v. 9 n. 3, p. 271-273 How to Cite?
AbstractProstacyclin (PGI2) and its analogues are useful treatments for patients with secondary Raynaud's syndrome (RS). However, they have to be given intravenously, causing inconvenience to patients. Cicaprost is an orally available analogue of PGI2 and has been shown to inhibit platelet aggregation in both in vitro and animal studies. We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS. Patients received cicaprost (2.5 mg or 5 μg t.i.d.) or matching placebo tablets orally for 10 days. Blood samples were taken at baseline and 2 hours after administration of the last treatment for the above mentioned assays. No changes were observed in any of the cellular elements and parameters measured in the 3 groups of patients studied. Our study suggests that cicaprost, at doses up to 5 μg t.i.d. fails to modify the blood coagulation elements and factors in patients with RS secondary to SSc. Further studies using higher doses and longer study periods are planned.
Persistent Identifierhttp://hdl.handle.net/10722/161857
ISSN
2015 Impact Factor: 2.495
2015 SCImago Journal Rankings: 0.953
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, CSen_US
dc.contributor.authorMclaren, Men_US
dc.contributor.authorSaniabadi, Aen_US
dc.contributor.authorScott, Nen_US
dc.contributor.authorBelch, JJFen_US
dc.date.accessioned2012-09-05T05:15:33Z-
dc.date.available2012-09-05T05:15:33Z-
dc.date.issued1991en_US
dc.identifier.citationClinical And Experimental Rheumatology, 1991, v. 9 n. 3, p. 271-273en_US
dc.identifier.issn0392-856Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/161857-
dc.description.abstractProstacyclin (PGI2) and its analogues are useful treatments for patients with secondary Raynaud's syndrome (RS). However, they have to be given intravenously, causing inconvenience to patients. Cicaprost is an orally available analogue of PGI2 and has been shown to inhibit platelet aggregation in both in vitro and animal studies. We recently investigated the effects of cicaprost on whole blood platelet aggregation, red cell deformability, white cell function (polymorphonuclear cell aggregation, elastase release and free radical activity) and plasma fibrinolysis in 14 patients with systemic sclerosis (SSc) and secondary RS. Patients received cicaprost (2.5 mg or 5 μg t.i.d.) or matching placebo tablets orally for 10 days. Blood samples were taken at baseline and 2 hours after administration of the last treatment for the above mentioned assays. No changes were observed in any of the cellular elements and parameters measured in the 3 groups of patients studied. Our study suggests that cicaprost, at doses up to 5 μg t.i.d. fails to modify the blood coagulation elements and factors in patients with RS secondary to SSc. Further studies using higher doses and longer study periods are planned.en_US
dc.languageengen_US
dc.publisherPacini Editore SpA. The Journal's web site is located at http://www.clinexprheumatol.orgen_US
dc.relation.ispartofClinical and Experimental Rheumatologyen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshEpoprostenol - Administration & Dosage - Analogs & Derivatives - Pharmacology - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFibrinolysis - Drug Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPlatelet Aggregation - Drug Effectsen_US
dc.subject.meshPlatelet Aggregation Inhibitors - Pharmacologyen_US
dc.subject.meshRaynaud Disease - Drug Therapy - Etiologyen_US
dc.subject.meshScleroderma, Systemic - Complicationsen_US
dc.titleThe pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis - a preliminary studyen_US
dc.typeArticleen_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1879086-
dc.identifier.scopuseid_2-s2.0-0025731034en_US
dc.identifier.volume9en_US
dc.identifier.issue3en_US
dc.identifier.spage271en_US
dc.identifier.epage273en_US
dc.identifier.isiWOS:A1991FP11300010-
dc.publisher.placeItalyen_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US
dc.identifier.scopusauthoridMcLaren, M=7005471705en_US
dc.identifier.scopusauthoridSaniabadi, A=18936909200en_US
dc.identifier.scopusauthoridScott, N=35451126800en_US
dc.identifier.scopusauthoridBelch, JJF=7101752870en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats